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Traumatic brain injury (TBI) represents one of the major causes of mortality and disability in the world. TBI is characterized by
primary damage resulting from the mechanical forces applied to the head as a direct result of the trauma and by the subsequent
secondary injury due to a complex cascade of biochemical events that eventually lead to neuronal cell death. Oxidative stress plays
a pivotal role in the genesis of the delayed harmful effects contributing to permanent damage. NADPH oxidases (Nox), ubiquitary
membrane multisubunit enzymes whose unique function is the production of reactive oxygen species (ROS), have been shown to
be amajor source of ROS in the brain and to be involved in several neurological diseases. Emerging evidence demonstrates that Nox
is upregulated after TBI, suggesting Nox critical role in the onset and development of this pathology. In this review, we summarize
the current evidence about the role of Nox enzymes in the pathophysiology of TBI.
1. Introduction
Traumatic brain injury (TBI) has become the leading cause of
disability among young individuals and working age adults
[1]. World Health Organization (WHO) has predicted that
TBI will be the third leading cause of global mortality and
disability by 2020 [2]. In the European Union over a million
hospital admissions per year are due to TBI [3], making it one
of the major causes of trauma-related mortality in this area
[4].
TBI is characterized by primary damage to the brain
resulting from mechanical forces applied to the head at
the time of trauma as well as delayed damage triggered
by different mechanisms that evolve over time [5–7]. TBI
secondary injury includes a complex cascade of biochemical
events involving oxidative stress, glutamate excitotoxicity,
and neuroinflammation, leading to neuronal cell death [8].
Mitochondrial dysfunction at the neuronal/astrocytic level
has been reported to be a key participant in neuroinflamma-
tion [9] and also in TBI pathophysiology [10, 11], leading to a
marked reactive oxygen species (ROS) accumulation.
Oxidative stress, the imbalance between the level of
ROS/reactive nitrogen species (RNS) and antioxidants, has
been extensively investigated as one of the major contribu-
tors to the pathophysiology of secondary TBI damage. The
most commonly occurring cellular free radical is superoxide
(O
2
∙−), which promotes the formation of other ROS/RNS
leading to lipid peroxidation [12]. Mitochondria has been
generally considered the main source of O
2
∙− following
brain injury [13]; however in the last years NADPH oxidase
(Nox) family members have emerged as major contributor to
O
2
∙− generation. Several studies have demonstrated that Nox
is upregulated after TBI [14–18] and pharmacological and
genetic Nox inhibition has been shown tomarkedly attenuate
TBI secondary injury [18, 19], suggesting Nox critical role in
the onset and development of this pathology.
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The following review summarizes current research on the
damaging role of oxidative stress in TBI, focusing onNADPH
oxidase as ROS generator enzymes.
2. Pathophysiology of Traumatic Brain Injury
Traumatic brain injury (TBI) is a damage to the brain
due to an external physical insult that can lead to loss of
consciousness, impairment of cognitive and motor abilities,
and disruption of behavioral and/or emotional functioning.
These neurological deficits can be temporary or permanent
andmay lead to physical and psychosocial disability [20].The
outcomemay vary fromdeath to survivingwith disabilities or
even to complete recovery. The most common causes of TBI
in adults are road traffic accidents, falls, violence, and armed
conflicts [7].
The head trauma can be penetrating or closed according
to the mechanism while the clinical severity is usually
classified according to the Glasgow Coma Score (GCS) [21].
TBI patients are categorized into mild, moderate, and severe.
A GCS score of 13–15 is conventionally associated with mild
TBI, a score of 9–12 with moderate TBI, and a score of 8 or
less with severe TBI [22].
TBI is characterized by primary and secondary damage.
The primary damage is the direct expression of the mechani-
cal forces applied to the head (impact, blast, and penetrating
trauma) that cause localized and/or diffuse macroscopic
brain lesions [23]. In particular in the case of severe TBI, focal
and diffuse damage coexist: the localized damage includes
focal contusions and hematomas, whereas diffuse damage
includes brain swelling, microvascular damage and diffuse
axonal injury (DAI). DAI is characterized by widespread
damage to axons in thewhitematter [24, 25] that can be found
up to 72% of moderate to severe TBI [26].
The severity of DAI can be classified in grade 1 or mild
(changes diffusely distributed in the white matter but not in
the corpus callosum or in the brainstem), grade 2 or moderate
(with evidence of involvement of the corpus callosum), and
grade 3 or severe (with additional aspects of lesion in the
dorsolateral segments of the rostral brainstem) [27].
DAI might be considered a progressive process evolving
from axonal damage to ultimate disconnection [28] and
therefore, even if scarcely visible with conventional computed
tomography (CT), can cause white matter disconnection that
sustains cognitive, behavioral, and motor impairments and
can heavily affect the short- and long-term outcome [29].
Moderate to severe TBI, as repeated mild TBI, can lead
to long-term cognitive impairments and might be associated
with increased risk of neurodegenerative diseases [30–32].
TBI also initiates a cascade of damage with variable
extent and duration and with molecular mechanisms not
yet completely understood. These processes take place for
hours and days (or even weeks and months) after the brain
trauma and may include hypotension, hypoxia, ischemia,
excitotoxicity, and inflammation among others.
The secondary damage is non-mechanical, evolves over
time [33], and comprises cytoskeletal damage and alteration
of cell signaling pathways [34, 35]. A complex series of cellular
and molecular changes play a fundamental role in these
cascades and include blood-brain barrier (BBB) impairment
[36–38], ionic imbalance [39], excitotoxicity [40], brain
edema [41], neuroinflammation [9, 42, 43], and oxidative
stress [44, 45].
In particular, the ischemic pattern observed in TBI
impairs the capacity of neurons and glial cells to maintain
membrane ionic equilibrium. As a consequence, depolar-
ization occurs in neurons, resulting in activation of presy-
naptic voltage-dependent Ca2+ channels and in massive
release of excitatory neurotransmitters like glutamate and
aspartate into the extracellular space [46, 47]. The toxic
level of excitatory amino acids activates postsynaptic NMDA
(N-methyl-D-aspartate) and metabotropic receptors, which
induce calcium overload of the postsynaptic neurons [48].
The final event in ischemic damage is always a massive intra-
cellular Ca2+ accumulation [22] which leads to mitochon-
drial dysfunction and oxidative stress [49, 50]. Furthermore,
excessive cytosolic calcium activates proteolytic enzymes and
phospholipases that induce degradation of cytoskeleton and
extracellular matrix proteins and enhances ROS production.
[47]. Large lines of evidences demonstrate that ROS gen-
eration and oxidative stress contribute significantly to the
pathophysiology of secondary injury after TBI [48, 51, 52].
3. Reactive Oxygen Species and
Oxidative Stress
ROS, historically considered as purely harmful byproduct
of metabolism causing cell damage, are now considered as
important modulators of intracellular signaling pathways,
since they can be intentionally generated in particular by the
Nox family [53]. Accumulating evidence suggests that ROS
are involved in several pathophysiological responses ranging
from cell proliferation to cell death and that deregulated ROS
signaling contributed to a multitude of human diseases, such
as brain injury and neurodegenerative disease [54–59].
When cells, including neurons, are in a homeostatic
balance, the availability of antioxidant enzymes (e.g., catalase,
superoxide dismutase, glutathione peroxidase, glutathione
reductase, and glutathione-S-transferase) and of scavenging
molecules (e.g., glutathione, ascorbic acid, and tocopherols)
approximately matches ROS level, allowing redox signaling
[60].
Oxidative stress, on the contrary, represents the imbal-
ance between ROS level and antioxidant defense and may
arise from increased ROS formation or from deficiencies in
antioxidant levels [61].
A variety of pathologies have been reported to be rela-
ted to oxidative stress that causes irreversible oxidative mod-
ifications of proteins, lipids, and/or DNA, generating oxida-
tive stress markers (e.g., carbonylated proteins, lipid perox-
idation) and leading to cellular necrosis or apoptosis and
consequently to tissue injury [53, 62]. Superoxide can directly
or indirectly damage DNA through oxidation [63], directly
inactivate cellular antioxidants enzymes [64], and activate
proinflammatory nuclear factors [65]; therefore, it has been
implicated in numerous pathological processes including
acute and chronic diseases [66].
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Other ROS/RNS that possess different redox characteris-
tics and, thus, different physiological and pathophysiological
effects can derive from superoxide. For example, colocaliza-
tion of superoxide at sites of nitric oxide (NO) production
can lead to the formation of peroxynitrite (ONOO−) and
to oxidative damage due to peroxynitrite decomposition
products that possess potent free radical features [62]. More-
over, superoxide is rapidly reduced, both spontaneously and
enzymatically, to H
2
O
2
. Unlike superoxide, H
2
O
2
is able
to cross cellular membranes, through specific aquaporin
channels [67], acting at sites distant from its source and
modifying DNA and proteins [68]. Moreover, H
2
O
2
, in
the presence of transition metals, can generate hydroxyl
radical (OH∙) which is highly reactive and indiscriminately
oxidizes nucleotides causing breaks and lesions of DNA and
lipid peroxidation. The brain is highly susceptible to lipid
peroxidation because of its elevated oxygen consumption
and richness in polyunsaturated fatty acids [69] and iron
[70]. Lipid peroxidation causes alterations in cell membrane
fluidity, increases permeability of membranes, and decreases
membrane activity, leading to cell injury.
The understanding of oxidative stress mechanisms and
the development of antioxidant strategies are of primary
interest to optimize brain injury treatment and may provide
useful therapeutic strategies for brain injury inflammation
and neurodegenerative diseases [56, 71–73].
4. Oxidative Stress in Traumatic Brain Injury
ROS generation has a profound impact on the onset of TBI
secondary injury. The impaired blood flow following TBI
triggers cerebral hypoxia or ischemia with the consequent
reduction of oxygen and glucose supply to the brain. The
transition from aerobic to anaerobic metabolism generates
a state of acidosis which activates pH-dependent calcium
channels [74]. The increased Ca2+ levels into neuronal cyto-
plasm lead to an increase in ROS/RNS productionmainly due
to the impairment of the mitochondrial electron transport
chain and the activation of the calcium dependent proteases
and phospholipases [74–76]. During blood flow restoration
or reperfusion, enzymes involved in ROS production find
enough oxygen to generate large quantities of ROS/RNS
strongly contributing to oxidative stress in TBI [75]. The
most common free radical generated almost immediately
following TBI is superoxide [77, 78]. Within the injured
nervous system, different possible sources contribute to the
production of superoxide radical. Ca2+ induces activation
of phospholipases and the downstream arachidonic acid
cascade, xanthine oxidase activity, mitochondrial leak, enzy-
matic or autoxidation of biogenic amine neurotransmitters,
oxidation of hemoglobin, andNox familymember activation.
At later time, TBI triggers a series of inflammatory
processes that contribute to neuronal damage and failure
of functional recovery. These processes are mediated by
infiltrating inflammatory cells like activated microglia, neu-
trophils, and macrophages that produce multiple proinflam-
matory mediators, such as cytokines, chemokines, inducible
NOS and cyclooxygenase-2 (COX-2), and can be additional
sources of O
2
∙− [11, 79, 80].
In aqueous environments, like the cytoplasm, O
2
∙− exists
in equilibrium with the hydroperoxyl radical (HO
2
∙) which
is more lipid soluble and a more powerful oxidizing agent
[81]. However, under the acidic condition characteristic of
TBI, there is a shift of the equilibrium in favor of HO
2
∙
increasing lipid peroxidation. Lipid peroxidation can induce
brain tissue damage by different mechanisms: impairing
mitochondrial membrane lipid structure leading to mito-
chondrial dysfunction [82, 83]; enhancing the accumulation
of 4-HNE that inhibits astrocytic glutamate transporters
[84, 85], potentially increasing the neurotoxicity mediated by
glutamate; compromising Ca2+ homeostasis by damaging the
Ca2+-ATPase in the cell membrane [86]; andmobilizing Ca2+
from intracellular stores like the endoplasmic reticulum [87].
Another important player in post-TBI pathophysiology
scenario is peroxynitrite, produced by coupling NO with
superoxide. The damaging role of ONOO− in TBI has been
indirectly demonstrated by the neuroprotective effect of acute
treatment of injured mice and rats with NOS inhibitors [88,
89] and by the use of the peroxynitrite derived free radicals
scavenger, tempol, that ameliorated the accumulation of
nitrotyrosine in injured brains and concomitantly improved
neurological recovery in mice [90]. It has also been reported
a significant upregulation of all the three NOS isoforms
(endothelial, neuronal, and inducible) after TBI [91–93] with
a consequent increase of NO level.
Red blood cell lysis, due to mechanical trauma, is
another important source of oxidative stress in TBI. The
main consequence of red blood cells lysis is the release of
free hemoglobin [94] whose oxidation to oxyhemoglobin
and methemoglobin contributes to ROS generation [95–
98]. Moreover, hemoglobin degradation by either H
2
O
2
or lipid hydroperoxides (LOOH) gives rise to the release
of iron anions which further contributes to the formation
of ROS/RNS [75]. Iron is tightly regulated in the brain
under physiological conditions but after traumatic injury
iron homeostasis is disrupted by acidosis that increases iron
solubility and mediates its delocalization from an inactive to
an active redox state [99, 100]. In conclusion, in TBI themany
different ROS sources synergistically contribute to the onset
of an extensive and profound condition of oxidative stress.
5. NADPH Oxidase Enzymes
ROS have been long thought to be only a harmful by-
product of the electron transport chain in mitochondria
or in enzymatic processes such as nitric oxide synthase
(NOS), cytochrome p450, cyclooxygenase, xanthine oxidase,
and lipoxygenase. Whereas the enzymatic processes listed
above produce ROS as a side-reaction of normal enzymatic
function, the accidental production of ROS is not the only
modality of ROS generation. In fact, there are a family of
membrane enzymes that reduce molecular oxygen to form
ROS as their unique enzymatic function: these enzymes are
called NADPH oxidases (Nox) since they use NADPH as a
source of electrons to reduce molecular oxygen.
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The first enzyme to be discovered that “intentionally”
generates ROS inmammalian cells is theNox expressed in the
phagocytes. The phagocytic NADPH oxidase (now known as
Nox2) is a membrane enzyme that produces large amounts of
ROS in a “respiratory burst” characterized by consumption
of O
2
and production of superoxide and hydrogen peroxide
that, in turn, can lead to the production of more reactive
species such as peroxynitrite and hypochlorous acid (HOCl)
[101].
Nox2 is a membrane enzymatic complex; the catalytic
subunit (known as gp91phox) is an integral protein containing
both flavin adenine nucleotide (FAD) and a heme group.
Other components of the functional complex are the mem-
brane protein p22phox which functions as a docking site
for the cytosolic regulator proteins p40phox, p47phox, and
p67phox and the small GTPase Rac. When assembled and
activated, Nox2 is able to transport electrons from cytosolic
NADPH to reduce molecular oxygen to form superoxide to
the other side of the membrane.
Nox2 is expressed in neutrophils and other phagocytic
cellsmediating host defence againstmicroorganisms; in these
white cells Nox2 produces high levels of ROS in order
to kill phagocytised microbes. The importance of Nox2 in
the host defence is highlighted by the fact that mutations
in the NADPH oxidase subunit genes can lead to chronic
granulomatous diseases (CGD) [102].
Several homologs of gp91phox (Nox2 catalytic subunit)
have been identified in non-phagocytic cells; now, the human
Nox family consists of seven different isoforms (Nox1, Nox2,
Nox3, Nox4, Nox5, Duox1, and Duox2) [101]. In addition,
new regulatory proteins have been discovered, NOXO1 (NOX
organizer 1) is homolog of p47phox, and NOXA1 (NOX
activator 1) is homolog of p67phox. Owing to their structure
and regulation Nox enzymes are categorized into two groups:
isoforms that require p22phox (Nox1, Nox2, Nox3, and
Nox4) and enzymes regulated by calcium through a calcium-
binding domain (Nox5, Duox1, and Duox2) [103].
Nox isoforms are distributed in a variety of tissues and
cells but, often, high expression of a certain isoform is only
found in specific organs or cells. For instance, Nox1 is highly
expressed in colon, Nox4 in the kidney, Nox3 in the inner
ear, and Duox2 in the thyroid [104]. Nox-derived ROS levels
in nonphagocytic cells are typically much lower than in
neutrophils since they are not generated to host defense, but
as second messengers molecules in response to physiological
stimuli such as endothelial growth factor, platelet-derived
growth factor, angiotensin II, and insulin.
The most abundant isoforms expressed in the brain are
Nox1, Nox2, Nox3, and Nox4. Several studies have investi-
gated the expression of Nox isoforms in specific CNS regions,
most of them are focused on Nox2 but data exist also for
Nox1, Nox3, and Nox4 [105]. Although available studies do
not provide a complete description of the CNS distribution
of Nox enzymes, it appears that Nox isoforms are often
coexpressed in various CNS regions and that Nox expression
in a certain CNS regions appears to be inducible rather than
constitutive. Expressions of NOX isoforms in specific CNS
cell types have been investigated in vitro on primary cultures.
Nox1, Nox2, andNox4 are present in neurons, astrocytes, and
microglia but, unfortunately, the relative amount of different
Nox enzymes and their peculiar function in different brain
cells are not sufficiently understood [105].
6. NADPH Oxidase in Traumatic Brain Injury
It has been widely demonstrated that NADPH oxidase plays
a key role in central nervous system pathophysiology [17, 106,
107] and increasing lines of evidence suggest that NADPH
oxidase is major producer of O
2
∙− and has a crucial role in the
development of secondary injury after TBI [18, 19, 108, 109].
Dohi et al. [110] were the first to evidence a direct
involvement of NADPH oxidase in TBI injury. They demon-
strated that gp91phox (also known as Nox2) is increased
in the ipsilateral hemisphere after TBI and specifically in
amoeboid-shaped microglial cells. Moreover, gp91phox−/−
mice exhibit reduced primary cortical damage and a lower
ROS level after TBI. Several studies have indirectly investi-
gated Nox involvement in TBI by the use of Nox inhibitors
like apocynin [111–113] that acts through the inhibition of
p47phox subunit translocation to catalytic subunit. Choi
et al. [19] observed that intraperitoneal delivery of apoc-
ynin to rats before TBI decreased ROS production, BBB
disruption, microglia activation, and exerted pronounced
neuroprotection. The protective effect of Nox inhibition by
apocynin was further investigated by Ferreira et al. [108]
that evidenced that early treatment with apocynin reduced
inflammatory and oxidative damage caused by moderate
fluid percussion injury in mice (mLFPI). They also observed
that apocynin did not show any protective effect on brain
water content, suggesting that NADPH oxidase activity is
not involved in the development of brain edema induced by
TBI. On the contrary, other authors showed that NADPH
oxidase inhibition reduces brain edema induced by cold brain
injury and controlled cortical impact [18, 114]. One possible
reason for these discrepancies could be found in the different
apocynin doses used in the studies.
Recent studies have shown a time-dependent change in
Nox function following TBI (Figure 1). Zhang et al. [18]
evidenced that Nox activity in the cerebral cortex and
hippocampus rapidly increases following TBI with an early
peak at 1 h, followed by a secondary peak at 24–96 h. In
particular, they suggested that the first peak is of neuronal
origin as demonstrated by a strong colocalization of Nox2
and O
2
∙− in neurons at 1 h after TBI; whereas the cellular
source for the Nox and O
2
∙− elevation at 24–96 h appears to
be activatedmicroglia.These data were confirmed by a recent
study by Lu et al. [15] that evaluated the temporal pattern
of Nox2 activation in adult male mouse cerebral cortex
following TBI. They observed a rapid and robust elevation
of Nox2 expression in the cerebral cortex at 1 h, followed by
a decrease to lower, but still elevated levels at 3–12 h after
TBI. A second significant elevation was observed at 24 h
after TBI with no significant difference in Nox2 expression
at 72 h. These data have been challenged by Ansari et al. [14]
that reported that both the Nox activity and O
2
∙− increased
in a time-dependent fashion, with the maximum values at
24 h.The authors postulated that these discrepancies could be
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Figure 1: Time related changes of Nox expression after TBI.
ascribed to the different animal model used and to the lack
of inhibitors for other sources of O
2
∙− during the detection
procedure used by Zhang et al. [18] and suggested that such
an early peak is most probably associated with mitochondrial
dysfunction that is known to occur within 30min after TBI
[16]. Song et al. demonstrated a significant Nox activation
between 48 and 72 h after a diffuse brain injury [17] but they
did not measure Nox activity before 48 h. Dohi et al. [110]
showed that Nox is highly expressed in chronically activated
microglia up to 4 months after TBI, and recently Loane et
al. [115] extended this time period observing that Nox is
upregulated in highly activated microglia surrounding the
lesion site up to 1 y. Microglial Noxmight cause neurotoxicity
through two related mechanisms: activation of Nox leads
to the production of extracellular ROS that are cytotoxic
to neighboring neurons. Moreover microglial intracellular
ROS produced by Nox are a key driver of self-propagating
cycles of microglial-mediated neurodegeneration as Nox
activation induces changes in microglia morphology and
proinflammatory gene expression [116]. Given this dual effect
of Nox activation on neurotoxicity, the role of Nox in
increasing ROS level and the prevalence of Nox activation
upon microglial activation suggested that microglial Nox
could play a key role in neuronal death after TBI [117]. In
the aged brain these effects are exacerbated as there is an
exaggerated microglia activation in response to TBI with
a Nox robust overexpression. In particular, in the injured
cortex of agedmice a strong upregulation of the Nox subunits
p22phox, and gp91phox has been observed [118].
The expression of Nox isoforms is dependent on cell
type and injury status [119]. In particular, Nox2 is primarily
expressed by microglia and neurons, Nox3 is primarily
expressed by neurons, and Nox4 is expressed by all three cell
types. Further, Nox2 is the most responsive to injury.
TBI is a well-known epigenetic risk factor for the devel-
opment of later neurodegenerative diseases [120]. Nox2 acti-
vation in brain tissue and Nox2-induced oxidative stress have
emerged as a critical factor in the pathogenesis of Alzheimer’s
disease [121, 122] and Parkinson’s disease [116, 123].
Alzheimer’s disease major hallmarks are the accumula-
tion of 𝛽-amyloid and neurofibrillary tangles in the brain and
the loss of neurons from the hippocampus and cerebral cortex
[124]. It has been shown that TBI induces an accumulation of
𝛽-amyloid in the brain, which may explain the increased risk
for cognitive decline and dementia in TBI patients [125, 126].
Interestingly, Nox inhibition by apocynin significantly atten-
uated the elevation of 𝛽-amyloid protein levels in the cortex
following TBI, suggesting that Nox activation is involved in
the induction of 𝛽-amyloid formation [18].
TBI was also found to induce overexpression of 𝛼-
synuclein, the principal component of Lewy bodies, reported
as a cause of Parkinson’s disease [127, 128]. A recent study of
Acosta et al. suggested 𝛼-synuclein as the pathological link
between chronic effects of TBI and PD symptoms [129]. It
has been shown that the knockdown of Nox in the substantia
nigra largely attenuated the increase of 𝛼-synuclein in a
paraquat-induced Parkinson’s disease model, suggesting that
Nox is involved in the mechanism responsible for generation
of oxidative stress conditions implicated in increased 𝛼-
synuclein expression and aggregation and dopaminergic
neurodegeneration [130].
In summary, Nox upregulation occurs immediately after
TBI and lasts for several days significantly contributing to
oxidative stress damage and neuronal cell death. In particular,
different lines of evidences suggest that Nox may be a
causative factor in the onset of neurodegenerative disease
related to TBI.
Although in terms of potential therapeutic strategies
TBI treatment requires a deeper understanding of cerebral
pathophysiology as well as of the neuroprotective responses
toward therapeutic agents, targeting Nox isoforms could
offer an intriguing hypothesis to decreasing/delaying the
progression of temporary or permanent neurologic deficits
that may result in lifelong impairment of physical, cognitive,
and psychosocial functioning.
7. Conclusions
Accumulating evidence suggests that Nox-derived ROS play
a crucial role in TBI. Nox upregulation occurs immediately
after TBI and lasts for several days significantly contribut-
ing to oxidative stress damage and neuronal cell death.
ROS produced by Nox contribute to diseases by means of
distinct mechanisms, such as oxidation of macromolecules
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Figure 2: Schematic representation of the proposed mechanisms triggering cell damage after TBI.
and consequent modulation of redox signaling pathways
(Figure 2). Despite the progress made in the understanding
of oxidative stress involvement in the pathology of several
neurodegenerative diseases, much remains to be learned
about how to counteract neurological damage following
TBI.
TBI is a well-known epigenetic risk factor for the develop-
ment of later neurodegenerative diseases such as Parkinson
and Alzheimer. Interestingly, Nox2-induced oxidative stress
has emerged as a critical factor both in TBI secondary injury
and in the pathogenesis of Alzheimer and Parkinson diseases
suggesting that Nox2-generated ROS after TBI could be the
cause of the increased neurodegenerative risks associated
with TBI.
In summary, this review highlights the crucial role of Nox
in TBI and suggests that selective and specific Nox inhibitor
compounds could be useful for the development of novel
therapeutic targets and strategies, allowing a fine correction
of detrimental aspects of TBI.
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